Non-alcoholic fatty liver disease increases the risk of biochemical recurrence in high-grade metastatic prostate cancer patients

IF 1.4 4区医学 Q4 ONCOLOGY

Asia-Pacific journal of clinical oncology Pub Date : 2024-07-05 DOI:10.1111/ajco.14094

Hongyi Zhang, Wenbo Yang, Bin Zhang, Jiahui Wu, Wei Zhang, Zhenlong Wang, Jie Cui

{"title":"Non-alcoholic fatty liver disease increases the risk of biochemical recurrence in high-grade metastatic prostate cancer patients","authors":"Hongyi Zhang, Wenbo Yang, Bin Zhang, Jiahui Wu, Wei Zhang, Zhenlong Wang, Jie Cui","doi":"10.1111/ajco.14094","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Non-alcoholic fatty liver disease (NAFLD) has been reported to be helpful to identify high-risk individuals of developing prostate cancer. Our aim is to investigate the relationship between NAFLD and biochemical recurrence in metastatic prostate cancer patients.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We retrospectively investigated 602 patients with metastatic prostate cancer receiving the androgen deprivation therapy. Liver fat was estimated with liver-to-spleen ratio by computed tomography (CT) scans. The relationship between NAFLD and biochemical recurrence was investigated with Cox models. The model for biochemical recurrence was adjusted for multiple variables.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>NAFLD was significantly associated with biochemical recurrence in patients with Gleason score ≥4+3 when adjusting for each of body mass index (hazards ratio [HR] = 1.38; 95% confidence interval [CI] = 1.08–1.77; <i>p</i> = 0.01), visceral adipose tissue (HR = 1.36; 95% CI = 1.07–1.74; <i>p</i> = 0.01), hypertension (HR = 1.41; 95% CI = 1.10–1.80; <i>p</i> = 0.01), and diabetes mellitus (HR = 1.42; 95% CI = 1.11–1.82; <i>p</i> = 0.01), using age and prostate-specific antigen level as potential confounder. The 2-year biochemical recurrence rate in the Gleason score ≥4+3 patients with and without NAFLD was 84.0% (100/119) and 72.2% (130/180), respectively (<i>p </i>= 0.018). The median biochemical recurrence free survival of the Gleason score ≥4+3 patients with and without NAFLD were 17 and 21 months, respectively (<i>p </i>= 0.005).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>NAFLD is an independent risk factor for biochemical recurrence in patients with high-grade metastatic prostate cancer. If validated in prospective studies, future research should test whether treatment of NAFLD can lead to better prognosis.</p>\n </section>\n </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia-Pacific journal of clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ajco.14094","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Non-alcoholic fatty liver disease (NAFLD) has been reported to be helpful to identify high-risk individuals of developing prostate cancer. Our aim is to investigate the relationship between NAFLD and biochemical recurrence in metastatic prostate cancer patients.

Methods

We retrospectively investigated 602 patients with metastatic prostate cancer receiving the androgen deprivation therapy. Liver fat was estimated with liver-to-spleen ratio by computed tomography (CT) scans. The relationship between NAFLD and biochemical recurrence was investigated with Cox models. The model for biochemical recurrence was adjusted for multiple variables.

Results

NAFLD was significantly associated with biochemical recurrence in patients with Gleason score ≥4+3 when adjusting for each of body mass index (hazards ratio [HR] = 1.38; 95% confidence interval [CI] = 1.08–1.77; p = 0.01), visceral adipose tissue (HR = 1.36; 95% CI = 1.07–1.74; p = 0.01), hypertension (HR = 1.41; 95% CI = 1.10–1.80; p = 0.01), and diabetes mellitus (HR = 1.42; 95% CI = 1.11–1.82; p = 0.01), using age and prostate-specific antigen level as potential confounder. The 2-year biochemical recurrence rate in the Gleason score ≥4+3 patients with and without NAFLD was 84.0% (100/119) and 72.2% (130/180), respectively (p = 0.018). The median biochemical recurrence free survival of the Gleason score ≥4+3 patients with and without NAFLD were 17 and 21 months, respectively (p = 0.005).

Conclusions

NAFLD is an independent risk factor for biochemical recurrence in patients with high-grade metastatic prostate cancer. If validated in prospective studies, future research should test whether treatment of NAFLD can lead to better prognosis.

查看原文本刊更多论文

非酒精性脂肪肝会增加高级别转移性前列腺癌患者的生化复发风险。

导言：据报道，非酒精性脂肪肝（NAFLD）有助于识别前列腺癌高危人群。我们的目的是研究非酒精性脂肪肝与转移性前列腺癌患者生化复发之间的关系：我们对602名接受雄激素剥夺治疗的转移性前列腺癌患者进行了回顾性调查。肝脏脂肪通过计算机断层扫描（CT）以肝脾比值进行估算。通过 Cox 模型研究了非酒精性脂肪肝与生化复发之间的关系。生化复发模型根据多个变量进行了调整：结果：当调整体重指数（危险比 [HR] = 1.38; 95% 置信区间 [CI] = 1.08-1.77; p = 0.01）、内脏脂肪组织（HR = 1.36; 95% CI = 1.07-1.74; p = 0.01）、高血压（HR = 1.41; 95% CI = 1.10-1.80; p = 0.01）和糖尿病（HR = 1.42; 95% CI = 1.11-1.82; p = 0.01），将年龄和前列腺特异性抗原水平作为潜在混杂因素。Gleason评分≥4+3的非酒精性脂肪肝患者和非酒精性脂肪肝患者的2年生化复发率分别为84.0%（100/119）和72.2%（130/180）（P = 0.018）。有NAFLD和无NAFLD的Gleason评分≥4+3患者的中位无生化复发生存期分别为17个月和21个月（P = 0.005）：结论：非酒精性脂肪肝是高级别转移性前列腺癌患者生化复发的独立危险因素。结论：非酒精性脂肪肝是高级别转移性前列腺癌患者生化复发的独立危险因素，如果在前瞻性研究中得到验证，未来的研究应检验治疗非酒精性脂肪肝是否能改善预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asia-Pacific journal of clinical oncology 医学-肿瘤学

CiteScore

3.40

自引率

0.00%

发文量

175

审稿时长

6-12 weeks

期刊介绍： Asia–Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia–Pacific region in relation to cancer treatment and care. The Journal is ideally positioned to receive publications that deal with diversity in cancer behavior, management and outcome related to ethnic, cultural, economic and other differences between populations. In addition to original articles, the Journal publishes reviews, editorials, letters to the Editor and short communications. Case reports are generally not considered for publication, only exceptional papers in which Editors find extraordinary oncological value may be considered for review. The Journal encourages clinical studies, particularly prospectively designed clinical trials.